Legato Capital Management LLC Purchases Shares of 5,190 Krystal Biotech, Inc. (NASDAQ:KRYS)

Legato Capital Management LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,190 shares of the company's stock, valued at approximately $936,000.

A number of other large investors have also bought and sold shares of the company. Teacher Retirement System of Texas boosted its holdings in shares of Krystal Biotech by 27.3% in the fourth quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock worth $1,000,000 after acquiring an additional 1,369 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after acquiring an additional 432 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Krystal Biotech by 18.7% in the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock worth $23,786,000 after acquiring an additional 23,934 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in shares of Krystal Biotech by 1.8% in the fourth quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock worth $2,044,000 after acquiring an additional 229 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on KRYS. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America dropped their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Citigroup reaffirmed a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research note on Friday. Finally, Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Friday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $211.33.

Krystal Biotech Stock Up 1.9%

Shares of NASDAQ KRYS traded up $2.82 during midday trading on Monday, reaching $150.43. The company had a trading volume of 117,992 shares, compared to its average volume of 315,821. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $213.52. The firm's fifty day moving average price is $138.26 and its 200-day moving average price is $155.67. The stock has a market cap of $4.35 billion, a PE ratio of 36.16 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This represents a 0.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders sold 49,800 shares of company stock worth $7,487,943. Corporate insiders own 13.70% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).